U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Tuesday.Shares of Energy Fuels Inc (NYSE:UUUU) fell sharply in pre-market trading after the company announced a proposed $550 million private offering of convertible senior notes due 2031.Energy Fuels shares dipped 6.4% to $15.47 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Epsium Enterprise Limited (NASDAQ:EPSM) fell 24.3% to $18.60 in pre-market trading after dipping 30% ...

Core Viewpoint - Nohui Health, once hailed as the "first stock in cancer early screening," has been suspended from trading on the Hong Kong Stock Exchange for 18 months, potentially facing mandatory delisting due to regulatory rules [1] Group 1: Company Background - Nohui Health was established in 2015 in Hangzhou, Zhejiang, and became the first company in China focused on home early screening for high-incidence cancers, successfully listing on the Hong Kong Stock Exchange in 2021 [3] - The company has commercialized three main products targeting the top three high-incidence cancers in China: Changweiqing®, Pupu Tube®, and Youyou Tube® [3] - Changweiqing® is the only colorectal cancer screening product approved by the National Medical Products Administration in China, suitable for high-risk individuals aged 40-74 [3] Group 2: Financial Issues and Allegations - In August 2023, a short-selling firm, CapitalWatch, released a report alleging financial fraud, claiming that Nohui Health inflated its sales revenue through inventory manipulation, with actual sales for 2022 estimated at 76.95 million, significantly lower than the reported 765 million [4] - Despite management's strong denial and claims of third-party audits, Deloitte refused to endorse the company's financial statements in March 2024, raising concerns about the authenticity of sales data [4] Group 3: Stock Performance and Management Changes - Following the suspension on March 28, 2024, Nohui Health's stock price fell from an initial listing price of 26.66 HKD to 14.14 HKD, nearly halving in value [5] - The company has seen a series of executive departures, including the resignation of the founder and CEO, Zhu Yeqing, in 2025, and the appointment of joint provisional liquidators by the Cayman Islands court [5] - Investors have suffered significant losses, with the valuation of Nohui Health dropping from 14.14 HKD at suspension to nearly zero, with the latest valuation at 0.01 HKD [5] Group 4: Regulatory and Product Concerns - Nohui Health's core product, Changweiqing®, has a registration certificate expiring in November 2025, raising concerns about its future sales and regulatory compliance [5]

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Schlieren (Zürich), Switzerland – September 30, 2025 – Kuros Biosciences (“Kuros” or the “Company”), a leader in innovative biologic technologies, today announced the full commercial launch of the MagnetOs™ MIS Delivery System. Purpose-built for Minimally Invasive Surgical (MIS) procedures, the system is designed to meet every surgeon’s need in bone graft delivery. It will be showcased at the Kuros booth and featured in ...

Group 1 - The 2025 World Cantonese Business Conference opened in Guangzhou, hosted by the Guangdong Provincial Government, attracting representatives from 60 countries and regions, including Fortune 500 companies and experts [2][4] - The theme of the conference is "Cantonese Connects the World, Business Creates the Future," featuring a format of "1+5+N" with one opening ceremony, five thematic sessions, and numerous supporting activities [2][4] - The conference aims to promote high-quality development and encourage Cantonese businesses to seize opportunities for collaboration and investment [9][10] Group 2 - The conference recognized 100 outstanding builders of the non-public economy in Guangdong, highlighting the importance of the private sector in driving economic growth and social responsibility [5][6] - The awards are given every three years, with criteria focusing on political quality, development capability, social responsibility, and public reputation [5][6] - Among the awardees, 78 are leaders of medium and small enterprises, and 38 companies received the Guangcai Award for significant contributions to public welfare [6] Group 3 - The Guangdong Provincial Federation of Industry and Commerce released a report on innovative entrepreneurial cases among young Cantonese entrepreneurs, showcasing their contributions to innovation and entrepreneurship [7] - The conference also presented the "Global Cantonese Business Cooperation Initiative," calling for unity among Cantonese businesses to enhance development and contribute to their hometowns [8] Group 4 - The conference highlighted the 2025 Guangdong Province's top 100 private enterprises, with an entry threshold of 12.332 billion yuan, and 24 projects signed at the conference totaling 44.458 billion yuan [9][10] - The top 100 list includes companies with revenues exceeding 400 billion yuan, with significant representation from cities like Shenzhen and Guangzhou [10] Group 5 - Industry leaders emphasized the need for businesses to expand globally while strengthening internal capabilities, advocating for a shift from product output to capability output [11][12] - The conference underscored the importance of collaboration between Hong Kong and Guangdong enterprises to leverage their respective strengths in technology and manufacturing [13] - The event served as a rallying point for Cantonese businesses to align with national strategies and engage in global cooperation [14]

蓝纳成递表港交所，中金公司（601995）为其独家保荐人。蓝纳成是一家成立于2021年的生物科技公 司，致力于肿瘤诊疗放射性药物的发现、开发及商业化。 全球前列腺癌药物市场预计将从2024年的193亿美元增长至2030年的324亿美元。公司计划在中国一线城 市的三甲医院进行初步商业化，并逐步扩展。 蓝纳成正在建设一座符合cGMP标准的新生产设施，预计于2026年第一季度完工，最大年产能可达 7.674×1014Bq。 公司目前已建立一个包含13款候选药物的管线，包括7款诊断放射性药物和6款治疗放射性药物。 其核心产品包括针对前列腺癌的诊断放射性药物18F-LNC1001和18F-LNC1005，以及治疗性药物177Lu LNC1011。 ...

来源：科技日报 图片由AI生成 ◎本报记者 张梦然 人们所知道的绝大多数关于植物的基本原理知识，都是在一种你可能从未听说过的植物——拟南芥中首 次发现的。 绘制植物的基因表达图谱 在作为模式植物的几十年间，拟南芥经历了无数实验。科学家们持续致力于解码其基因组，并绘制出不 同组织和器官中各类细胞的基因表达图谱。借助这些局部图谱，人们得以逐步揭示控制植物各部位身份 与功能的关键基因。 其中，单细胞RNA测序成为构建细胞图谱的核心工具。该技术不直接分析DNA，而是检测基因组的表 达产物——RNA分子，从而精准识别哪些基因在特定细胞中被激活，以及其表达水平的高低。由于生 物体所有细胞共享同一套遗传密码，细胞类型的区分依赖于其独特的基因表达模式，单细胞RNA测序 因此成为识别和分类细胞类型的有力手段。 然而，传统方法存在明显局限：科学家必须将组织解离为单个细胞，导致原本的空间结构被破坏。这意 味着虽然能获知"有哪些细胞"，却难以回答"它们在哪儿"以及"如何组织"。 为突破这一瓶颈，索尔克生物研究所团队将单细胞RNA测序与空间转录组学相结合，实现了从"碎片化 图谱"向"全景式地图"的跨越。 更先进技术带来更完整图谱 空间 ...

Core Viewpoints - The discussion among investors regarding whether to hold stocks or cash during the upcoming holidays has intensified, with HSBC providing a point forecast for A-shares, predicting the Shanghai Composite Index at 4500 points, CSI 300 at 5400 points, and Shenzhen Component Index at 16000 points by 2026 [1][2]. Part 01: Market Dynamics - The current market is expected to see a shift from the optical module sector to other growth sectors such as the Apple supply chain, energy storage, and CXO (pharmaceutical sub-sectors), with the optical module sector still anticipated to rise [3]. - Innovation is identified as a core driver for the Chinese stock market's valuation increase, with China becoming a crucial part of the global supply chain due to enhanced innovation capabilities [4]. Part 02: Earnings, Valuation, and Liquidity - A structural recovery in earnings is projected for 2026, with a minimal downward adjustment of 0.2% in consensus earnings forecasts year-to-date [5]. - The expected earnings growth for high-growth sectors like electronics (+36.8%) and healthcare (+20.0%) is sufficient to support current valuations, while the power equipment sector is expected to see a 49.8% earnings growth that has not been fully priced in [6][7]. - The A-share market's valuation remains reasonable, with the overall market PE at 22.2x, CSI 300 at 14.0x, and the mid-cap index at 34.4x, all below historical median levels [8][9]. - Domestic liquidity is improving, with significant increases in non-bank deposits and a rise in retail investor participation, while foreign capital is expected to flow back into emerging markets due to anticipated interest rate cuts by the Federal Reserve [10]. Part 03: Index Targets, Market Style, and Sector Allocation - HSBC forecasts a 17%-20% upside potential for major indices by the end of 2026, with specific targets set for the Shanghai Composite Index, CSI 300, and Shenzhen Component Index [11][12]. - The trend of growth stocks outperforming value stocks is expected to continue, supported by high turnover rates and improving risk appetite among investors [13]. - Sector allocation recommendations include overweighting information technology and healthcare, while downgrading consumer discretionary due to valuation concerns [14]. Part 04: Investment Themes and Key Stocks - HSBC focuses on four major investment themes: 1. Artificial Intelligence (AI) with key stocks like Lanqi Technology and Zhongji Xuchuang benefiting from increased capital expenditure in cloud services [17]. 2. Healthcare with companies like Hansoh Pharmaceutical and WuXi AppTec positioned to capitalize on global pharmaceutical innovation [18]. 3. International expansion with firms like Yiwei Lithium Energy and Ninebot Company expected to grow overseas revenue [19]. 4. High-dividend quality stocks such as Hangzhou Bank, which are anticipated to perform steadily amid economic recovery [20].

记者丨张伟泽 这一极端行情背后，折射出指数型基金被动投资机制所蕴含的风险。多只追踪国证港股通创新药指数的 ETF因成分股调整而被迫高位买入，成为市场关注焦点。该现象不仅激起投资者对ETF运作机制的深入 讨论，也引发市场对相关指数编制合理性及透明度的质疑。 SFC 出品丨21财经客户端 21世纪经济报道 编辑丨张嘉钰 21君荐读 编辑丨和佳 一场史无前例的股价"蹦极"正引发港股市场广泛关注。 生物科技公司药捷安康（2617.HK）自6月上市以来，股价经历了从13.15港元飙升至679.5港元，又骤降 至143.2港元的惊人走势，7个交易日内涨幅一度超10倍，随后短短4日却暴跌79%。9月26日收盘，药捷 安康跌超10%，报143.2港元/股。自上市以来，药捷安康累计涨幅仍高达561.43%。 | | 143.200 -16.600 -10.39% | 130.928(CNY) | | | | | 药捷安康-B 立即 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 2617 交易 | | HKEX HKD 16:08:12 | ...

记者丨 张伟泽 | HKEX HKD 16:08:12 | | | | | | | | 通 / 口 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 委比 | 90.91% 委差 | | 1.00万 | 交生 | | 0.00% 120日 | | 0.00% | | 卖工 | 144.500 | | - ) | 5日 | | -4.47% 250日 | | 0.00% | | 卖四 | 144.400 | - | - ) | 20日 | | 164.45% 52周高 | | 679.50 | | 英三 | 144.300 | - | - ) | 60日 | | 321.80% 52周低 | | 20.20 | | 卖二 | 144.200 | - | - ) | | | 2023 | 2024 | 2025H1 | | 享一 | 144.100 | 500 | 1) | EbS | | -0.90 | -0.72 | -0.32 | | 蓝一 | 143.100 | 1000 | 2) | BPS | | | | 1.47 | | 买二 | ...

新华社长沙9月26日电 题：产业规模近万亿元 中国生物制造如何竞逐"新蓝海"？ 新华社记者唐诗凝 大豆经生物酶转化，成为保健品市场的新宠；玉米变身燃料乙醇，助力减少航空业碳排放；利用基 因工程菌株生产的胰岛素，成为治疗糖尿病的有效手段……在我国，生物制造正成为产业创新发展 的"新赛道"。 "中国的生物制造产业总规模已接近1万亿元。"工业和信息化部消费品工业司司长何亚琼在2025中 国生物制造科技创新论坛上说，科技创新和产业创新融合发展，正带动一批有竞争力的生物制造产业集 聚区逐步成长壮大。 9月25日至26日，2025中国生物制造科技创新论坛在湖南常德举行。来自全国的知名专家、创新企 业家和投融资机构代表等齐聚一堂，共话生物制造领域新技术、新机遇。 生物制造是一种新兴的生产技术，通过生物过程来合成或加工产品，与传统的化学或物理制造方法 相比，具有绿色、高效、可再生等特点。 "生物制造是科技创新和产业创新融合发展的重要领域""生物制造具有引领'第四次工业革命'的潜 力"……论坛上，与会嘉宾们纷纷表示，伴随生物制造快速发展，不断迭代的技术创新对新产业、新模 式、新动能的催生带动作用显著增强。 慕恩广州（生物）科技 ...